Morgan Stanley Maintains Overweight on Disc Medicine, Raises Price Target to $92
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $90 to $92.
Morgan Stanley analyst Sean Laaman maintains Disc Medicine (NASDAQ:IRON) with a Overweight and raises the price target from $90 to $92.